Switch to:
Also traded in: Denmark, Germany, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 21.80
NVO's Cash to Debt is ranked lower than
53% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 49.71 vs. NVO: 21.80 )
Ranked among companies with meaningful Cash to Debt only.
NVO' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 11.99 Max: N/A
Current: 21.8
Equity to Asset 0.45
NVO's Equity to Asset is ranked lower than
74% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NVO: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
NVO' s Equity to Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.65 Max: 0.73
Current: 0.45
0.42
0.73
F-Score: 7
Z-Score: 15.38
M-Score: -2.42
WACC vs ROIC
10.25%
141.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 43.57
NVO's Operating margin (%) is ranked higher than
95% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -73.78 vs. NVO: 43.57 )
Ranked among companies with meaningful Operating margin (%) only.
NVO' s Operating margin (%) Range Over the Past 10 Years
Min: 21.38  Med: 32.40 Max: 45.81
Current: 43.57
21.38
45.81
Net-margin (%) 31.33
NVO's Net-margin (%) is ranked higher than
93% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. NVO: 31.33 )
Ranked among companies with meaningful Net-margin (%) only.
NVO' s Net-margin (%) Range Over the Past 10 Years
Min: 16.65  Med: 24.74 Max: 32.3
Current: 31.33
16.65
32.3
ROE (%) 86.71
NVO's ROE (%) is ranked higher than
99% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -32.24 vs. NVO: 86.71 )
Ranked among companies with meaningful ROE (%) only.
NVO' s ROE (%) Range Over the Past 10 Years
Min: 22.36  Med: 42.79 Max: 79.9
Current: 86.71
22.36
79.9
ROA (%) 41.18
NVO's ROA (%) is ranked higher than
98% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. NVO: 41.18 )
Ranked among companies with meaningful ROA (%) only.
NVO' s ROA (%) Range Over the Past 10 Years
Min: 14.9  Med: 25.96 Max: 41.29
Current: 41.18
14.9
41.29
ROC (Joel Greenblatt) (%) 170.39
NVO's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. NVO: 170.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 36.68  Med: 87.93 Max: 178.92
Current: 170.39
36.68
178.92
Revenue Growth (3Y)(%) 14.00
NVO's Revenue Growth (3Y)(%) is ranked higher than
67% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. NVO: 14.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 7.1  Med: 13.20 Max: 18.7
Current: 14
7.1
18.7
EBITDA Growth (3Y)(%) 15.50
NVO's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. NVO: 15.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 9.6  Med: 15.50 Max: 25.7
Current: 15.5
9.6
25.7
EPS Growth (3Y)(%) 20.30
NVO's EPS Growth (3Y)(%) is ranked higher than
77% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. NVO: 20.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 10.2  Med: 20.30 Max: 29.7
Current: 20.3
10.2
29.7
» NVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

NVO Guru Trades in Q2 2015

Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,740 sh (unchged)
Ruane Cunniff 81,800 sh (-0.30%)
Mario Gabelli 6,545 sh (-2.31%)
Ken Fisher 12,295,864 sh (-2.88%)
Jim Simons 14,087,000 sh (-2.94%)
» More
Q3 2015

NVO Guru Trades in Q3 2015

Murray Stahl 7,827 sh (+1.12%)
Tom Gayner 1,075,000 sh (unchged)
Ruane Cunniff 81,320 sh (-0.59%)
Ken Fisher 11,652,268 sh (-5.23%)
Mario Gabelli 6,170 sh (-5.73%)
Jim Simons 13,171,000 sh (-6.50%)
» More
Q4 2015

NVO Guru Trades in Q4 2015

Mario Gabelli 6,210 sh (+0.65%)
Ruane Cunniff 81,320 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,827 sh (unchged)
Spiros Segalas 7,362,676 sh (unchged)
Ken Fisher 11,447,413 sh (-1.76%)
Jim Simons 12,898,800 sh (-2.07%)
» More
Q1 2016

NVO Guru Trades in Q1 2016

Jeremy Grantham 122,600 sh (New)
Ruane Cunniff 97,525 sh (+19.93%)
Mario Gabelli 6,225 sh (+0.24%)
Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,787 sh (-0.51%)
Jim Simons 12,775,700 sh (-0.95%)
Ken Fisher 11,178,809 sh (-2.35%)
Spiros Segalas 6,179,837 sh (-16.07%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:AMGN, NAS:GILD, NAS:CELG, NAS:BIIB, OTCPK:RHHBY, OTCPK:CSLLY, NAS:REGN, NAS:SHPG, NYSE:BXLT, NAS:ALXN, NAS:VRTX, OTCPK:ALIOY, NAS:INCY, OTCPK:UCBJF, OTCPK:NVZMY, NAS:BMRN, NAS:GRFS, OTCPK:GMXAY, NAS:MDVN, NAS:JAZZ » details
Traded in other countries:NOVO B.Denmark, NOVA.Germany, NOVOB.Switzerland, 0QIU.UK, NONOF.USA,
Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes care and biopharmaceuticals.

Novo-Nordisk A/S is a healthcare company incorporated on November 28, 1931 in Denmark. The Company has diabetes product portfolios, including new generation insulins, a full portfolio of modern insulins as well as a human once-daily GLP-1 analog. In addition, it also has a position within haemophilia care, growth hormone therapy and hormone replacement therapy, and Company's first product to treat obesity, Saxenda, was launched in the United States in April 2015 and is also available in Denmark, Italy and Canada. The Company manufactures and markets pharmaceutical products and services that make a difference to patients, the medical profession and society. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes & obesity care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. The important markets are North America, China, Japan and the European countries. In addition there is an increasing contribution to its total sales from key markets in the sales region International Operations such as Saudi Arabia, Algeria, Turkey, Argentina, Australia, India, Brazil, Iran and Russia.

Top Ranked Articles about Novo Nordisk A/S

The PBM Empire Strikes Back Some of the largest pharmacy benefit managers are driving significant change in drug pricing
I had the privilege of speaking at the GuruFocus Conference in Omaha. The basis of my talk was finding value in health care. Read more...
Jim Simons' Five Most-Heavily Weighted Holdings Colgate-Palmolive tops the list
More than 30 years ago, Jim Simons (Trades, Portfolio) founded investment firm Renaissance Technologies. Today it is one of the most successful hedge funds in the world. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.95
NVO's P/E(ttm) is ranked higher than
58% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 28.83 vs. NVO: 24.95 )
Ranked among companies with meaningful P/E(ttm) only.
NVO' s P/E(ttm) Range Over the Past 10 Years
Min: 12.13  Med: 23.50 Max: 34.43
Current: 24.95
12.13
34.43
Forward P/E 22.88
NVO's Forward P/E is ranked lower than
55% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 20.70 vs. NVO: 22.88 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.95
NVO's PE(NRI) is ranked higher than
59% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 28.83 vs. NVO: 24.95 )
Ranked among companies with meaningful PE(NRI) only.
NVO' s PE(NRI) Range Over the Past 10 Years
Min: 12.03  Med: 23.46 Max: 34.44
Current: 24.95
12.03
34.44
Price/Owner Earnings (ttm) 28.17
NVO's Price/Owner Earnings (ttm) is ranked higher than
56% of the 133 Companies
in the Global Biotechnology industry.

( Industry Median: 32.22 vs. NVO: 28.17 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.81  Med: 28.68 Max: 68.66
Current: 28.17
13.81
68.66
P/B 23.41
NVO's P/B is ranked lower than
94% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 3.34 vs. NVO: 23.41 )
Ranked among companies with meaningful P/B only.
NVO' s P/B Range Over the Past 10 Years
Min: 3.66  Med: 8.06 Max: 31.9
Current: 23.41
3.66
31.9
P/S 7.90
NVO's P/S is ranked higher than
61% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. NVO: 7.90 )
Ranked among companies with meaningful P/S only.
NVO' s P/S Range Over the Past 10 Years
Min: 2.8  Med: 5.47 Max: 11.01
Current: 7.9
2.8
11.01
PFCF 24.79
NVO's PFCF is ranked higher than
54% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 26.08 vs. NVO: 24.79 )
Ranked among companies with meaningful PFCF only.
NVO' s PFCF Range Over the Past 10 Years
Min: 12.07  Med: 24.48 Max: 47.08
Current: 24.79
12.07
47.08
POCF 20.76
NVO's POCF is ranked higher than
53% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 22.99 vs. NVO: 20.76 )
Ranked among companies with meaningful POCF only.
NVO' s POCF Range Over the Past 10 Years
Min: 9.91  Med: 19.61 Max: 32.54
Current: 20.76
9.91
32.54
EV-to-EBIT 20.71
NVO's EV-to-EBIT is ranked higher than
51% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 21.76 vs. NVO: 20.71 )
Ranked among companies with meaningful EV-to-EBIT only.
NVO' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 16.60 Max: 25.7
Current: 20.71
9.2
25.7
EV-to-EBITDA 19.32
NVO's EV-to-EBITDA is ranked lower than
51% of the 305 Companies
in the Global Biotechnology industry.

( Industry Median: 18.58 vs. NVO: 19.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 15.90 Max: 23.6
Current: 19.32
8.2
23.6
PEG 1.34
NVO's PEG is ranked higher than
65% of the 92 Companies
in the Global Biotechnology industry.

( Industry Median: 2.23 vs. NVO: 1.34 )
Ranked among companies with meaningful PEG only.
NVO' s PEG Range Over the Past 10 Years
Min: 0.48  Med: 1.20 Max: 5.17
Current: 1.34
0.48
5.17
Shiller P/E 47.68
NVO's Shiller P/E is ranked higher than
54% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 54.39 vs. NVO: 47.68 )
Ranked among companies with meaningful Shiller P/E only.
NVO' s Shiller P/E Range Over the Past 10 Years
Min: 22.8  Med: 43.02 Max: 68.04
Current: 47.68
22.8
68.04
Current Ratio 1.13
NVO's Current Ratio is ranked lower than
87% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NVO: 1.13 )
Ranked among companies with meaningful Current Ratio only.
NVO' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.99 Max: 2.45
Current: 1.13
1.04
2.45
Quick Ratio 0.81
NVO's Quick Ratio is ranked lower than
88% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. NVO: 0.81 )
Ranked among companies with meaningful Quick Ratio only.
NVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.32 Max: 1.91
Current: 0.81
0.74
1.91
Days Inventory 280.69
NVO's Days Inventory is ranked lower than
82% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.52 vs. NVO: 280.69 )
Ranked among companies with meaningful Days Inventory only.
NVO' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 292.48 Max: 343.56
Current: 280.69
246.45
343.56
Days Sales Outstanding 54.79
NVO's Days Sales Outstanding is ranked higher than
57% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. NVO: 54.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.24 Max: 53.6
Current: 54.79
45.09
53.6
Days Payable 82.49
NVO's Days Payable is ranked higher than
61% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 60.55 vs. NVO: 82.49 )
Ranked among companies with meaningful Days Payable only.
NVO' s Days Payable Range Over the Past 10 Years
Min: 65.17  Med: 93.12 Max: 124.07
Current: 82.49
65.17
124.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.89
NVO's Dividend Yield is ranked higher than
69% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.43 vs. NVO: 1.89 )
Ranked among companies with meaningful Dividend Yield only.
NVO' s Dividend Yield Range Over the Past 10 Years
Min: 0.79  Med: 1.48 Max: 2.47
Current: 1.89
0.79
2.47
Dividend Payout 0.47
NVO's Dividend Payout is ranked lower than
72% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. NVO: 0.47 )
Ranked among companies with meaningful Dividend Payout only.
NVO' s Dividend Payout Range Over the Past 10 Years
Min: 0.5  Med: 1.29 Max: 1.85
Current: 0.47
0.5
1.85
Dividend Growth (3y) 21.30
NVO's Dividend Growth (3y) is ranked higher than
78% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. NVO: 21.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVO' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 22.70 Max: 49.4
Current: 21.3
0
49.4
Forward Dividend Yield 1.79
NVO's Forward Dividend Yield is ranked higher than
67% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 1.32 vs. NVO: 1.79 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 9.53
NVO's Yield on cost (5-Year) is ranked higher than
95% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 1.59 vs. NVO: 9.53 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVO' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.98  Med: 7.46 Max: 12.45
Current: 9.53
3.98
12.45
3-Year Average Share Buyback Ratio -3.10
NVO's 3-Year Average Share Buyback Ratio is ranked higher than
78% of the 551 Companies
in the Global Biotechnology industry.

( Industry Median: -11.40 vs. NVO: -3.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: 1.50 Max: 8
Current: -3.1
-3.1
8

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 638.25
NVO's Price/Net Current Asset Value is ranked lower than
100% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. NVO: 638.25 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 11.62  Med: 24.52 Max: 710.4
Current: 638.25
11.62
710.4
Price/Tangible Book 24.91
NVO's Price/Tangible Book is ranked lower than
93% of the 945 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. NVO: 24.91 )
Ranked among companies with meaningful Price/Tangible Book only.
NVO' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.14  Med: 6.79 Max: 31.52
Current: 24.91
3.14
31.52
Price/Projected FCF 2.37
NVO's Price/Projected FCF is ranked higher than
64% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. NVO: 2.37 )
Ranked among companies with meaningful Price/Projected FCF only.
NVO' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.41  Med: 2.42 Max: 82.77
Current: 2.37
1.41
82.77
Price/DCF (Earnings Based) 0.88
NVO's Price/DCF (Earnings Based) is ranked higher than
76% of the 17 Companies
in the Global Biotechnology industry.

( Industry Median: 1.26 vs. NVO: 0.88 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.44
NVO's Price/Median PS Value is ranked lower than
75% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. NVO: 1.44 )
Ranked among companies with meaningful Price/Median PS Value only.
NVO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.14  Med: 0.88 Max: 1.91
Current: 1.44
0.14
1.91
Price/Peter Lynch Fair Value 1.21
NVO's Price/Peter Lynch Fair Value is ranked higher than
68% of the 59 Companies
in the Global Biotechnology industry.

( Industry Median: 1.68 vs. NVO: 1.21 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
NVO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.19  Med: 1.03 Max: 3.78
Current: 1.21
0.19
3.78
Price/Graham Number 5.25
NVO's Price/Graham Number is ranked lower than
75% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.88 vs. NVO: 5.25 )
Ranked among companies with meaningful Price/Graham Number only.
NVO' s Price/Graham Number Range Over the Past 10 Years
Min: 1.58  Med: 2.62 Max: 6.76
Current: 5.25
1.58
6.76
Earnings Yield (Greenblatt) (%) 4.84
NVO's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 1100 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. NVO: 4.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.9  Med: 6.00 Max: 10.8
Current: 4.84
3.9
10.8
Forward Rate of Return (Yacktman) (%) 23.25
NVO's Forward Rate of Return (Yacktman) (%) is ranked higher than
67% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 14.39 vs. NVO: 23.25 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.5  Med: 22.60 Max: 38.6
Current: 23.25
7.5
38.6

More Statistics

Revenue (TTM) (Mil) $16,380
EPS (TTM) $ 2.00
Beta0.52
Short Percentage of Float0.10%
52-Week Range $46.17 - 60.34
Shares Outstanding (Mil)2,600.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 19,912 20,984 22,601
EPS ($) 2.65 2.94 3.19
EPS w/o NRI ($) 2.65 2.94 3.19
EPS Growth Rate
(3Y to 5Y Estimate)
8.93%
» More Articles for NVO

Headlines

Articles On GuruFocus.com
High Yield, Strong Returns: Sturm Ruger, Nu Skin Enterprises Jun 23 2016 
Stocks Mario Gabelli Has Bought for 2 Quarters Jun 20 2016 
Jim Simons' Top Holdings Include VeriSign, Chipotle Dec 15 2015 
Value Investing in BioPharma Nov 18 2015 
Jim Simons' Five Most-Heavily Weighted Holdings Oct 21 2015 
Ken Fisher Reduces Stake in Toyota, Increases Position in Anheuser-Busch Oct 20 2015 
Jim Simons and Ken Fisher Decrease Exposure on Novo Nordisk A/S Sep 14 2015 
Nintai Returns: Q2 2015 Jul 01 2015 
Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 

More From Other Websites
These 5 Stocks Could Be Toxic to Your Portfolio This Summer Jun 24 2016
The Top Four Diabetes Best Sellers and One Oral Insulin Pill That May Threaten Them All Jun 22 2016
Novo Nordisk A/S - aktietilbagekøbsprogram Jun 20 2016
Novo Nordisk A/S - Share repurchase programme Jun 20 2016
Why This Pharma Giant Lost $8 Billion in Market Cap This Week Jun 16 2016
Novo Nordisk (NVO) Reports Positive Trial Results on Victoza Jun 15 2016
Novo Nordisk Drug Cuts Diabetic Deaths, But Not Enough For Wall Street Jun 14 2016
Can a Bunch of Doctors Keep an $8 Billion Secret? Not on Twitter Jun 14 2016
Victoza® significantly reduced the risk of major cardiovascular events and death in adults with... Jun 14 2016
Novo diabetes drug cuts heart risks by 13 pct in trial Jun 14 2016
Study Finds Victoza® Significantly Reduced the Risk of Heart Attack and Stroke in People with Type... Jun 13 2016
This Diabetes Drug Saves Lives. You Can Thank The FDA Jun 13 2016
Novo diabetes drug cuts heart risks by 13 pct in key trial Jun 13 2016
Novo Slumps as Study on Victoza’s Heart Impact Disappoints Jun 13 2016
Faster-acting insulin aspart showed a statistically significant reduction in HbA(1c) in type 1... Jun 13 2016
Faster-acting insulin aspart showed a statistically significant reduction in HbA(1c) in type 1... Jun 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)